Search Within

Elisa De Stanchina

  1. "Jose Baselga"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Department of Medicine (8)
  2. GSK Faculty (8)
  3. Sloan Kettering Institute Postdocs (8)
  4. Breast Medicine Service (7)
  5. Molecular Pharmacology and Chemistry Program Faculty (7)
  6. Sloan Kettering Institute Faculty (7)

More Groups

People
  1. Jose Baselga (8)
  2. Neal Rosen (6)
  3. Vanessa Rodrik - Outmezguine (5)
  4. Zhan Yao (4)
  5. Michael Berger (3)
  6. Sarat Chandarlapaty (3)

More People

Years
  1. 2020 (1)
  2. 2017 (2)
  3. 2015 (1)
  4. 2014 (3)
  5. 2013 (1)
Publications
  1. Cancer Research (4)
  2. Cancer Cell (1)
  3. Cancer Discovery (1)
  4. JCI Insight (1)
  5. Molecular Cancer Research (1)
Publishers
  1. American Association for Cancer Research (6)
  2. Amer Soc Clinical Investigation Inc (1)
  3. Cell Press (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer
    Meeting Abstract

    Vasan, N.; Johnson, J.; Shao, H.; Razavi, P.; Gorelick, A.; Ladewig, E.; Antoine, A.; Shah, H.; Toska, E.; Xu, G.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition
    Journal Article

    Yaeger, R.; Yao, Z.; Hyman, D. M.; Hechtman, J. F.; Vakiani, E.; Zhao, H.; Su, W.; Wang, L.; Joelson, A.; Cercek, A.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations
    Journal Article

    Mondello, P.; Brea, E. J.; De Stanchina, E.; Toska, E.; Chang, A. Y.; Fennell, M.; Seshan, V.; Garippa, R.; Scheinberg, D. A.; Baselga, J.; more...
    JCI Insight (2017)

    Fulltext@MSK | Save
  • Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ
    Journal Article

    Schwartz, S.; Wongvipat, J.; Trigwell, C. B.; Hancox, U.; Carver, B. S.; Rodrik-Outmezguine, V. ; Will, M.; Yellen, P.; de Stanchina, E.; Baselga, J.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling
    Meeting Abstract

    Schwartz, S.; Carver, B. S.; Wongvipat, J.; Rodrik-Outmezguine, V. ; Destanchina, E.; Trigwell, C.; Barry, S.; Baselga, J.; Chandarlapaty, S.; Scher, H. I.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
    Meeting Abstract

    Rodrik - Outmezguine, V. S.; Yao, Z.; Mukherjee, R.; Cai, L.; Barratt, D.; Ward, R.; Klinowska, T.; Destanchina, E.; Berger, M.; Baselga, J.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling
    Journal Article

    Will, M.; Qin, A. C. R.; Toy, W.; Yao, Z.; Rodrik-Outmezguine, V. ; Schneider, C.; Huang, X.; Monian, P.; Jiang, X.; de Stanchina, E.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
    Meeting Abstract

    Rodrik-Outmezguine, V.; Yao, Z.; Berger, M.; De Stanchina, E.; Klinowska, T.; Barratt, D.; Baselga, J.; Rosen, N.
    Cancer Research (2013)

    Fulltext@MSK | Save